On April 3-5, the 27th National School of Gastroenterologists and Hepatologists of Ukraine “Ways to Improve Efficiency and New Technologies for the Prevention, Diagnosis and Treatment of Digestive Diseases and Comorbidities” was held in Kyiv, sponsored by Valartin Pharma Company.

During the event, significant attention was paid to the consideration of modern approaches to the prevention, diagnosis and treatment of chronic liver diseases and their complications.

At the master class “Clinical Case. Patient with Liver Cirrhosis. Features of Diagnosis and Treatment”, the head of the Department of Gastroenterology, Dietetics and Endoscopy of the P.L. Shupyka, Corresponding Member of the National Academy of Medical Sciences of Ukraine, Doctor of Medical Sciences, Professor Nataliya Vyacheslavivna Kharchenko presented a report “Rules for the management of patients with liver cirrhosis”

The report lists the main points of the management of such patients, namely:

• diagnostic methods;
• selection of treatment tactics.

The speaker drew special attention to the use of a stepwise treatment regimen for the patient with the drug Heparizin, which has a pronounced anti-inflammatory and antifibrotic effect. The essence of stepwise therapy with the drug Heparizin is the initial use of infusion therapy of this drug with subsequent addition of the tablet form of Heparizin.

The drug has a glucocorticoid-like effect due to structural similarity with cortisol, inhibition of glucocorticosteroid metabolism enzymes. Suppresses the activation of stellate cells, suppresses excessive synthesis of collagen types I and III. Activates collagenases (MMPs), which leads to degranulation of excess collagen in the extracellular matrix.

Heparizin - a combined hepatoprotector containing glycyrrhizin, glycine, cysteine ​​(a complete analogue of SNMC, Japan). Reduces the likelihood of the occurrence and progression of fibrosis, liver cirrhosis and hepatocellular carcinoma.